
John A Mcknight

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6326549/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HbA1c Is Disproportionately Higher in Women and Older People With Type 1 Diabetes Compared With Flash Glucose Monitoring Metrics of Glycemic Control. Journal of Diabetes Science and Technology, 2022, 16, 446-453.	2.2	1
2	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia, 2022, 65, 159-172.	6.3	12
3	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabetic Medicine, 2022, 39, e14766.	2.3	28
4	Impact of routine clinic measurement of serum Câ€peptide in people with a clinicianâ€diagnosis of type 1 diabetes. Diabetic Medicine, 2021, 38, e14449.	2.3	28
5	Diabetes incidence in a highâ€risk UK population at 7 years: linkage of the Prevention of Diabetes and Obesity in South Asians (PODOSA) trial to the Scottish Diabetes Register. Diabetic Medicine, 2021, 38, e14369.	2.3	2
6	Assessment of the effect of the COVIDâ€19 lockdown on glycaemic control in people with type 1 diabetes using flash glucose monitoring. Diabetic Medicine, 2021, 38, e14374.	2.3	43
7	Socioeconomic deprivation, technology use, Câ€peptide, smoking and other predictors of glycaemic control in adults with type 1 diabetes. Diabetic Medicine, 2021, 38, e14445.	2.3	12
8	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology,the, 2021, 9, 82-93.	11.4	251
9	Substantial HbA1c Reduction Following Intermittent-Scanning Continuous Glucose Monitoring Was Not Associated With Early Worsening of Retinopathy in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2021, , 193229682199409.	2.2	0
10	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	6.3	5
11	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 2021, 64, 1320-1331.	6.3	19
12	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care, 2021, 44, 2010-2017.	8.6	8
13	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	8.6	55
14	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia, 2020, 63, 788-798.	6.3	31
15	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia, 2020, 63, 636-647.	6.3	22
16	The effect of DAFNE education, continuous subcutaneous insulin infusion, or both in a population with type 1 diabetes in Scotland. Diabetic Medicine, 2020, 37, 1016-1022.	2.3	9
17	Socioâ€economic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study. Diabetic Medicine, 2020, 37, 2081-2088.	2.3	14
18	Diabetes in Scotland: a rising tide. Lancet Diabetes and Endocrinology,the, 2020, 8, 375-376.	11.4	1

Јони А Мскиіднт

#	Article	IF	CITATIONS
19	HbA1c response and hospital admissions following commencement of flash glucose monitoring in adults with type 1 diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001292.	2.8	12
20	Time trends in deaths before age 50Âyears in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. Diabetologia, 2020, 63, 1626-1636.	6.3	6
21	Socioâ€economic differences in cardiovascular disease risk factor prevalence in people with type 2 diabetes in Scotland: a crossâ€sectional study. Diabetic Medicine, 2020, 37, 1395-1402.	2.3	4
22	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQqQ	080 ⁶ gBT	/Overlock 10
23	Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes. Diabetologia, 2020, 63, 906-914.	6.3	39
24	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 2019, 17, 165.	5.5	43
25	Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia, 2019, 62, 1349-1356.	6.3	116
26	Clycaemic control trends in people with type 1 diabetes in Scotland 2004–2016. Diabetologia, 2019, 62, 1375-1384.	6.3	45
27	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	6.3	33
28	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care, 2018, 41, 341-347.	8.6	92
29	N-Clycan Profile and Kidney Disease in Type 1 Diabetes. Diabetes Care, 2018, 41, 79-87.	8.6	75
30	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care, 2018, 41, 2010-2018.	8.6	47
31	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrology, 2017, 18, 163.	1.8	63
32	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 597-609.	11.4	248
33	Did the weight loss in the Prevention of Diabetes and Obesity in South Asians (PODOSA) trial differ by sex? An exploratory analysis. Public Health, 2017, 145, 67-69.	2.9	1
34	Flash Glucose Monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a <scp>UK</scp> diabetes centre. Diabetic Medicine, 2017, 34, 732-732.	2.3	40
35	Supported Telemonitoring and Glycemic Control in People with Type 2 Diabetes: The Telescot Diabetes Pragmatic Multicenter Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002098.	8.4	77
36	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). International Journal of Epidemiology, 2016, 46, dyw152.	1.9	15

Јони А Мскиіднт

#	Article	IF	CITATIONS
37	Using Large Diabetes Databases for Research. Journal of Diabetes Science and Technology, 2016, 10, 1073-1078.	2.2	16
38	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 2016, 59, 2106-2113.	6.3	71
39	Glycaemic control of TypeÂ1 diabetes in clinical practice early in the 21st century: an international comparison. Diabetic Medicine, 2015, 32, 1036-1050.	2.3	273
40	Can laboratory based research regarding type 1 diabetes and exercise be applied into the realâ€life environment?. Practical Diabetes, 2015, 32, 217-221.	0.3	1
41	The design and evaluation of a selfâ€management algorithm for people with type 1 diabetes performing moderate intensity exercise. Practical Diabetes, 2015, 32, 64-69.	0.3	3
42	Delayed hypoglycaemia in people with type 1 diabetes after performing moderate intensity exercise before the evening meal. Practical Diabetes, 2015, 32, 99-102.	0.3	3
43	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	7.4	454
44	Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype–phenotype correlations, codon bias and dominant-negative effects. Human Molecular Genetics, 2015, 24, 5079-5092.	2.9	69
45	End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 127-134.	0.5	52
46	Culturally adapting the prevention of diabetes and obesity in South Asians (PODOSA) trial. Health Promotion International, 2014, 29, 768-779.	1.8	35
47	Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. British Journal of Ophthalmology, 2014, 98, 790-795.	3.9	64
48	Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2Âyears following diagnosis of diabetes in Scotland, 2006–2008. Diabetic Medicine, 2014, 31, 640-646.	2.3	12
49	Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 218-227.	11.4	110
50	Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus. Hippokratia, 2014, 18, 306-9.	0.3	11
51	Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001–2007. Diabetologia, 2013, 56, 1712-1715.	6.3	12
52	External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. Diabetic Medicine, 2013, 30, 300-308.	2.3	97
53	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. PLoS ONE, 2013, 8, e83292.	2.5	30
54	Managing Acute Medical Admissions: The Plight of the Medical Boarder. Scottish Medical Journal, 2012, 57, 45-47.	1.3	7

Јони А Мскиіднт

#	Article	IF	CITATIONS
55	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. PLoS Medicine, 2012, 9, e1001321.	8.4	270
56	CSII from patient to politics; a national and local perspective. British Journal of Diabetes and Vascular Disease, 2012, 12, 91-96.	0.6	1
57	Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia, 2012, 55, 2938-2945.	6.3	45
58	Driving and hypoglycaemia: questions and answers. Practical Diabetes, 2012, 29, 13-14.	0.3	3
59	Assessment of the underâ€reporting of diabetes in hospital admission data: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetic Medicine, 2011, 28, 1514-1519.	2.3	42
60	Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population. Diabetes Care, 2011, 34, 1992-1997.	8.6	32
61	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 2011, 34, 1127-1132.	8.6	66
62	The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. Eurosurveillance, 2010, 15, .	7.0	43
63	Management of diabetes in pregnancy. Trends in Urology Gynaecology & Sexual Health, 2008, 13, 32-35.	0.1	Ο
64	Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study. Diabetic Medicine, 2008, 25, 194-199.	2.3	42
65	Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 20012006. Diabetic Medicine, 2008, 25, 743-746.	2.3	21
66	Diabetic papillopathy. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 24a-24a.	0.2	0